Q07820 (MCL1_HUMAN) Homo sapiens (Human)
Induced myeloid leukemia cell differentiation protein Mcl-1 UniProtKBInterProSTRINGInteractive Modelling
350 aa; Sequence (Fasta) ; (Isoform 2)
Available Structures
126 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Solution Structure of human Mcl-1 complexed with human Bid_BH3 peptide |
Heteromer P55957; | |||||
| Assess | ||||||
| Mcl-1 in complex with Bim BH3 mutant I2dY |
Heteromer O43521; | 1×TRS; | ||||
| Assess | ||||||
| Mcl-1 complexed with Mule |
Heteromer Q7Z6Z7; | |||||
| Assess | ||||||
| Human Mcl-1 in complex with a modified Bim BH3 peptide |
Heteromer O43521; | |||||
| Assess | ||||||
| Human Mcl-1 in complex with a modified unnatural Bim BH3 peptide |
Heteromer O43521; | 1×ADM; | ||||
| Assess | ||||||
| Human Mcl-1 in complex with a Bfl-1-specific selected peptide |
Heteromer | 4×ZN; 1×SO4; | ||||
| Assess | ||||||
| Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design |
Heteromer | |||||
| Assess | ||||||
| Human Mcl-1 in complex with the designed peptide dM1 |
Heteromer | 4×ZN; | ||||
| Assess | ||||||
| Mcl-1 bound to alpha beta Puma BH3 peptide 3 |
Heteromer P97287; Q9BXH1; | 10×ZN; 8×CL; | ||||
| Assess | ||||||
| Human Mcl-1 in complex with the designed peptide dM7 |
Heteromer | 1×CL; | ||||
| Assess | ||||||
| Mcl-1 in complex with Bim BH3 mutant I2dA |
Heteromer O43521; | 5×ZN; 1×ACT; 1×CL; | ||||
| Assess | ||||||
| Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival protei… |
Heteromer Q96LC9; | |||||
| Assess | ||||||
| Structure of human Mcl-1 in complex with PUMA BH3 peptide |
Heteromer Q9BXH1; | 3×ZN; 3×CL; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand |
Heteromer O43521; P97287; | 4×ZN; | ||||
| Assess | ||||||
| Mcl1 in complex with a Fab |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of MCL-1 in complex with a neutralizing Alphabody CMPX-383B |
Heteromer | 5×ZN; | ||||
| Assess | ||||||
| Mcl-1 in complex with Bim BH3 mutant F4aE |
Heteromer O43521; | 4×ZN; 1×ACT; | ||||
| Assess | ||||||
| Structure of human Mcl-1 in complex with BIM BH3 peptide |
Heteromer O43521; | 4×ZN; | ||||
| Assess | ||||||
| Crystal structure of Mcl1-inhibitor complex |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of human Mcl-1 in complex with modified Bim BH3 peptide SAH-MS1-18 |
Heteromer | 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 bound to BID-MM |
Heteromer P55957; | 1×GOL; | ||||
| Assess | ||||||
| X-ray crystal structure of human Mcl-1 in complex with Bim BH3 |
Heteromer | 3×ZN; 1×NA; | ||||
| Assess | ||||||
| Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs |
Heteromer | |||||
| Assess | ||||||
| MCL-1 complex with MCL-1-specific selected peptide |
Heteromer | 3×ZN; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of MCL-1 in complex with computationally designed inhibitor protein |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of the Mcl-1:mNoxaB BH3 complex |
Heteromer P97287; Q9JM54; | |||||
| Assess | ||||||
| Crystal structure of human Mcl-1 in complex with modified Bim BH3 peptide SAH-MS1-14 |
Heteromer | 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 in complex with 138E12 peptide, Lys-covalent antagonist |
Heteromer O43521; | |||||
| Assess | ||||||
| INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN FABCOMPLEX IN COMPLEX WITH COMPOUND 1 |
Heteromer | 1×VF8; | ||||
| Assess | ||||||
| Apo Mcl1 in a complex with a scFv |
Heteromer | |||||
| Assess | ||||||
| Structure of an anti-Mcl1 scFv |
Heteromer | 5×DMS; | ||||
| Assess | ||||||
| INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN FABCOMPLEX IN COMPLEX WITH AZD5991 |
Heteromer | 1×E4W; | ||||
| Assess | ||||||
| Mcl1-scFv complex with an indole acid inhibitor |
Heteromer | 1×HVN; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 in complex with the BaxBH3 domain |
Heteromer Q07812; | 10×CD; | ||||
| Assess | ||||||
| Crystal structure of the Mcl-1:Bim BH3 complex |
Heteromer O43521; P97287; | 7×ZN; 1×CL; | ||||
| Assess | ||||||
| Mcl-1 in complex with Bim-h3Pc-RT |
Heteromer O43521; P97287; | 3×EDO; | ||||
| Assess | ||||||
| Mcl-1 bound to alpha beta Puma BH3 peptide 2 |
Heteromer P97287; Q9BXH1; | 10×CD; | ||||
| Assess | ||||||
| MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 29 |
Heteromer P97287; | 1×7LT; | ||||
| Assess | ||||||
| BimL12Y in complex with Mcl-1 |
Heteromer O43521; P97287; | 4×ZN; | ||||
| Assess | ||||||
| MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 21 |
Heteromer P97287; | 1×7LW; | ||||
| Assess | ||||||
| Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human MCL1 |
Heteromer Q9H2K2; | |||||
| Assess | ||||||
| Crystal structure of MCL-1 in complex with a BIM competitive inhibitor | homo-2-mer | 2×9EA; 10×ZN; | ||||
| Assess | ||||||
| The MCL-1 BH3 Helix is an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizer | homo-2-mer | |||||
| Assess | ||||||
| NMR Structure of human Mcl-1 | monomer | |||||
| Assess | ||||||
| hMcl1 inhibitor complex | monomer | 1×N8J; | ||||
| Assess | ||||||
| Crystal structure of Mcl1 with inhibitor 8 | monomer | 1×N0M; | ||||
| Assess | ||||||
| X-ray co-crystal structure of compound 8 bound to human Mcl-1 | monomer | 1×Q4Y; | ||||
| Assess | ||||||
| X-ray co-crystal structure of compound 3 bound to human Mcl-1 | monomer | 1×Q51; | ||||
| Assess | ||||||
| X-ray co-crystal structure of compound 10 bound to human Mcl-1 | monomer | 1×Q4V; | ||||
| Assess | ||||||
| Co-crystal structure of Mcl1 with inhibitor 10 | monomer | 1×N0J; | ||||
| Assess | ||||||
| co-crystal structure of compound 1 bound to human Mcl-1 | monomer | 1×Q4D; | ||||
| Assess | ||||||
| X-ray co-crystal structure of compound 20 with Mcl-1 | monomer | 1×Q4S; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecule inhibitor | monomer | 1×5X3; | ||||
| Assess | ||||||
| Crystal structure of Mcl1 with inhibitor 9 | monomer | 1×N0S; | ||||
| Assess | ||||||
| Crystal structure of MCL-1 in complex with a BIM competitive inhibitor | monomer | 1×CN7; | ||||
| Assess | ||||||
| Structure of Mcl-1 in complex with compound 10d | monomer | 1×JL8; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 in complex with compound 10 | monomer | 1×LC6; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecules | monomer | 1×4M7; | ||||
| Assess | ||||||
| MCL1 in complex with indole acid ligand | monomer | 2×E4K; | ||||
| Assess | ||||||
| Crystal structure of Mcl1 with inhibitor 7 | monomer | 1×N0P; | ||||
| Assess | ||||||
| X-ray co-crystal structure of compound 5 with Mcl-1 | monomer | 1×Q54; | ||||
| Assess | ||||||
| X-ray co-crystal structure of compound 7 with Mcl-1 | monomer | 1×Q57; | ||||
| Assess | ||||||
| Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors that Demonstrate in vivo Activity in… | monomer | 1×KJP; | ||||
| Assess | ||||||
| Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Design | monomer | 1×6AK; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecules | monomer | 1×4M6; | ||||
| Assess | ||||||
| The crystal structure of anti-apoptotic Mcl-1 protein in complex with 2, 5-substituted benzoic acid… | monomer | 2×PZY; | ||||
| Assess | ||||||
| The crystal structure of human mcl1 kinase domain in complex with MCL1-M-EBA | monomer | 1×QHR; | ||||
| Assess | ||||||
| Structure of human Mcl-1 in complex with indole acid inhibitor | monomer | 2×J3E; | ||||
| Assess | ||||||
| Co-crystal structure of Mcl1 with inhibitor | monomer | 1×LOD; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 in complex with compound 65 | monomer | 1×NQJ; | ||||
| Assess | ||||||
| Co-crystal structure of Mcl1 with inhibitor | monomer | 1×LMV; | ||||
| Assess | ||||||
| Mcl-1 bound to compound 24 | monomer | 3×Q01; 1×BNL; | ||||
| Assess | ||||||
| Structure of Mcl-1 complex with compound 1 | monomer | 1×U6Q; 1×MG; 1×PG6; | ||||
| Assess | ||||||
| Crystal structure of Mcl-1 in complex with compound 4 | monomer | 1×LC3; | ||||
| Assess | ||||||
| Structure of Mcl-1 in complex with compound 8b | monomer | 1×JLE; | ||||
| Assess | ||||||
| Structure of Mcl-1 in complex with compound 8d | monomer | 1×JLK; | ||||
| Assess | ||||||
| Structure of Mcl-1 in complex with compound 8a | monomer | 1×JLE; | ||||
| Assess | ||||||
| Mcl-1 bound to compound 19 | monomer | 1×Q0A; 4×EDO; | ||||
| Assess | ||||||
| Structure of Mcl-1 in complex with compound 13 | monomer | 1×JL5; | ||||
| Assess | ||||||
| Co-crystal structure of Mcl1 with inhibitor | monomer | 1×LOJ; | ||||
| Assess | ||||||
| Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Design | monomer | 1×6AL; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecules | monomer | 1×ECY; | ||||
| Assess | ||||||
| Mcl-1 bound to compound 17 | monomer | 2×Q0D; | ||||
| Assess | ||||||
| Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design | monomer | 1×19H; 1×PGE; | ||||
| Assess | ||||||
| Structure of Mcl-1 complex with compound 6b | monomer | 1×U6N; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 11 | monomer | 1×GLC; 2×FMT; 1×YLT; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 32 | monomer | 1×GLC; 10×EDO; 1×YLF; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 10 | monomer | 1×GLC; 4×EDO; 1×GOL; 1×WUC; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecule inhibitor | monomer | 2×5WL; 1×5WK; | ||||
| Assess | ||||||
| STRUCTURE OF MCL1 BOUND TO BRD inhibitor ligand 1 AT 1.7A | monomer | 3×ZN; 1×865; 2×POP; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 34 | monomer | 1×GLC; 2×CL; 3×EDO; 1×PEG; 1×YKL; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 28 | monomer | 1×GLC; 3×EDO; 1×PEG; 1×YKX; | ||||
| Assess | ||||||
| Structure of human Mcl-1 in complex with thienopyrimidine inhibitor | monomer | 1×GLC; 1×J1N; 1×NA; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 12 | monomer | 1×GLC; 1×FMT; 1×EDO; 1×YLK; | ||||
| Assess | ||||||
| A Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1) | monomer | 1×GLC; 1×3M6; 1×MG; 10×FMT; | ||||
| Assess | ||||||
| MBP-Mcl1 in complex with ligand 21 | monomer | 1×GLC; 2×EDO; 1×YKT; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 4d | monomer | 1×GLC; 1×CL; 1×OK2; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 9m | monomer | 1×GLC; 1×OK5; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 18a | monomer | 1×GLC; 1×JLH; | ||||
| Assess | ||||||
| Structure of Mcl-1 in complex with compound 2g | monomer | 1×OJT; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of human Mcl-1 in complex with compound 1 | monomer | 1×GLC; 1×WXW; | ||||
| Assess | ||||||
| Crystal structure of the MBP-MCL1 complex with highly selective and potent inhibitor of MCL1 | monomer | 1×GLC; 1×70R; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 8b | monomer | 1×GLC; 1×JLE; 1×NA; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 8a | monomer | 1×GLC; 1×JLE; 1×NA; | ||||
| Assess | ||||||
| Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design | monomer | 1×19G; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 3e | monomer | 1×GLC; 1×CL; 1×OJW; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 10d | monomer | 1×GLC; 1×JL8; | ||||
| Assess | ||||||
| Mcl-1 bound to compound 17 | monomer | 3×Q0G; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecule inhibitor | monomer | 1×5X2; | ||||
| Assess | ||||||
| Crystal Structure of Human MCL-1 Bound to Inhibitor 4-(4-methylnaphthalen-1-yl)-2-{[(4-phenoxypheny… | monomer | 1×2UU; | ||||
| Assess | ||||||
| Mcl-1 complexed with small molecules | monomer | 1×ECM; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with MIK665 | monomer | 1×GLC; 1×OK5; | ||||
| Assess | ||||||
| MCL1 in complex with an indole acid ligand | monomer | 1×E4Q; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 6a | monomer | 1×GLC; 1×JKQ; 1×NA; | ||||
| Assess | ||||||
| The structure of MBP-MCL1 bound to ligand 5 at 1.9A | monomer | 1×GLC; 1×MG; 2×EDO; 7×FMT; 1×3R6; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with a macrocyclic compound | monomer | 1×GLC; 1×WLW; | ||||
| Assess | ||||||
| The structure of MBP-MCL1 bound to ligand 6 at 2.0A | monomer | 1×GLC; 1×3R7; 10×FMT; 1×MG; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with compound 7a | monomer | 1×GLC; 1×JLB; | ||||
| Assess | ||||||
| STRUCTURE OF MBP-MCL1 BOUND TO ligand 4 AT 2.4A | monomer | 1×GLC; 1×CL; 1×MG; 1×3R4; | ||||
| Assess | ||||||
| Structure of MBP-Mcl-1 in complex with ABBV-467 | monomer | 1×GLC; 1×WME; | ||||
| Assess | ||||||
| STRUCTURE OF MBP-MCL1 BOUND TO ligand 2 AT 1.55A | monomer | 1×GLC; 1×19H; 2×MG; 13×FMT; 1×NA; 4×EDO; | ||||
| Assess | ||||||
| Crystal Structure of Human MCL-1 Bound to Inhibitor 4-hydroxy-4'-propylbiphenyl-3-carboxylic acid | monomer | 1×2UV; | ||||
| Assess | ||||||
| STRUCTURE OF APO MBP-MCL1 AT 1.9A | monomer | 1×GLC; 1×MG; 2×EDO; 10×FMT; | ||||
| Assess | ||||||
| Crystal structure of MCL-1 in complex with a BIM competitive inhibitor | monomer | 1×CJY; | ||||
| Assess | ||||||
| STRUCTURE OF MBP-MCL1 BOUND TO ligand 1 AT 2.35A | monomer | 1×GLC; 1×865; 1×EDO; 11×FMT; | ||||
| Assess | ||||||
| Crystal structure of MCL1 with compound 1 | monomer | 1×NA; 1×6XJ; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5jsb.1.A | monomer | 0.81 | 100.00 | |||
| Assess | ||||||
1 SWISS-MODEL model built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 5c6h.1.M | monomer | 0.59 | 92.31 | ||
| Assess | ||||||